Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study

Table 2 Estimated mean differences in HbA1c, weight, and daily insulin between IDegLira and ICT during follow-up

	3 months			6 months			12 months			18 months
	MD	95% CI	P value	MD	95% CI	P value	MD	95% CI	P value	MD	95% CI	P value
HbA1c (%)	0.40	0.10; 0.70	0.0014	0.37	0.07; 0.67	0.0024	0.45	0.17; 0.72	0.0001	0.60	0.32; 0.88	< 0.0001
HbA1c (mmol/mol)	4.4	1.1; 7.7		4.0	0.8; 7.3		4.9	1.9; 7.9		6.6	3.5; 9.6
Body weight (kg)	3.4	1.7; 5.2	< 0.0001	4.6	2.8; 6.3	< 0.0001	5.7	4.0; 7.4	< 0.0001	6.7	5.0; 8.5	< 0.0001
Insulin dose (IU)	27.8	22.6; 33.0	< 0.0001	28.9	23.7; 34.0	< 0.0001	29.9	24.8; 35.0	< 0.0001	31.8	26.6; 37.0	< 0.0001

Estimated for a person with the following baseline characteristics: 62 years of age, HbA1c of 8.4% (68.3 mmol/mol), diabetes duration of 9.1 years, body weight of 91 kg, body mass index of 32.0 kg/m² using generalized least squares regression (n = 299 people, n = 889 observations). MD [95% CI] presented for IDegLira – ICT
CI confidence interval, ICT intensified conventional insulin treatment, IDegLira insulin degludec/liraglutide, IU insulin units, MD mean difference

ISSN: 1472-6823